Often adjuvant ADT is given prior to commencing RT. This is known as neoadjuvant hormonal therapy (NHT). There is no clear guidance on what duration to give this for, although 3-6 months is a common approach. Results from an Australian randomized trial have shown 6 months of NAT to result in superior survival than 3 months.[43] Intuitively, it would seem that some patients would benefit from a shorter duration of NHT than others depending on their tumour response. There has been some preliminary work looking at an adaptive approach for this, where RT is started once a maximal PSA response has been achieved.[44] This has been shown to be feasible and effective in the phase 2 setting.